BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Glucotrol (Glipizide) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Glucotrol (Glipizide)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06168812-284@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261205
DTEND;VALUE=DATE:20261206
SUMMARY:Glucotrol (Glipizide): Phase 2 readout est. (NCT06168812)
DESCRIPTION:Glucotrol (Glipizide)\, phase 2.\nStudy: A Study of Glipizide t
 o Treat High Blood Sugar in People With Pancreatic Cancer\nEstimated prima
 ry completion: 5 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/glipizide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06168812
URL:https://assetmemo.bio/drug/glipizide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830096-284@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glucotrol (Glipizide): Phase na readout est. (NCT06830096)
DESCRIPTION:Glucotrol (Glipizide)\, phase na\, Type 2 Diabetes.\nStudy: Rol
 e of KATP Channel Loss in Type 2 Diabetes\nEstimated primary completion: 3
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/glip
 izide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06830096
URL:https://assetmemo.bio/drug/glipizide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
